235 results about "Influenza a" patented technology

The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.

Provided are an anti-neuraminidase human monoclonal antibody obtained by means of multiple rounds of in-vitro screening and recombinant modification, and the use thereof in the preparation of a product for preventing, detecting, or treating influenza viruses. The provided monoclonal antibody exhibits significant neuraminidase inhibitory activity and broad-spectrum binding capacity to influenza virus antigens, shows excellent preventive and therapeutic effects against multiple seasonal influenza viruses, provides a new technical option for resisting influenza infection, and has great application value.

The invention belongs to the technical field of drug synthesis, and particularly relates to an adamantane derivative as well as a synthesis method and application thereof. The adamantane derivative comprises an intermediate structural formula I, an intermediate structural formula II and an intermediate structural formula III, and the structural general formula is as follows: Linker is substituted or unsubstituted C6-C10 aroyl, R1 is hydrogen or C1-C6 alkyl, R2 is hydrogen, C1-C6 alkyl or a nitrogen-containing or nitrogen-free structural fragment, or the integral structure of R1R2 is N-substituted heterocyclic pentyl or heterocyclic cyclohexyl. According to the adamantane derivative provided by the invention, an adamantane structure is combined with part of groups of OAB-14, and a parent nucleus structure is changed, so that the drug activity is improved. The invention also provides a synthesis method of the compound, the obtained compound is screened through cell viability research, and the compound has a potential synergistic effect in the aspects of preventing influenza and treating Alzheimer's disease.

This article provides a combination of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.

The application discloses a fusion protein for preventing and treating various pathogenic Pasteurellaceae bacterial infections, a nucleic acid vaccine and application thereof. The fusion protein comprises six antigens rplE, rpsC, rpsE, EF-Tu, DnaK and EF-G or three antigens EF-Tu, DnaK and EF-G, and the antigens are highly conservative in various Pasteurellaceae bacteria. The application further provides a recombinant nucleic acid molecule encoding the fusion protein, an immunogenic composition containing the same and a recombinant vaccine. The vaccine can induce broad-spectrum cross immune protection and is used for preventing and treating infectious diseases caused by Pasteurella multocida, Haemophilus parasuis, Mannheimia haemolytica, Haemophilus influenzae and Haemophilus paragallinarum.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

Described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 1 to 49. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 81 to 143. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137515 to 137675. Also described herein is a composition comprising nucleic acid sequences encoding at least two amino acid sequences selected from the group consisting of SEQ ID NOs: 137682 to 137830.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

The present application relates to the technical field of air conditioners, and provides a control method of an elevator air conditioner and the elevator air conditioner, the control method of the elevator air conditioner comprising: in response to an elevator door opening signal, acquiring the body temperature of a person entering the elevator; determining that the body temperature of the person is greater than or equal to a preset temperature, then controlling a fan of the elevator air conditioner to stop running, and controlling an ultraviolet disinfection device to disinfect the air in the elevator for a preset time length after all the persons in the elevator leave the elevator. When the person enters the elevator, the temperature detection device acquires the body temperature of the person in time, if the body temperature of the person exceeds the preset temperature, the air in the elevator has the risk of influenza transmission, the fan of the elevator air conditioner is controlled to be closed in time, and the speed of air flow in the elevator is slowed down. After all the persons in the elevator leave the elevator, the air in the elevator is disinfected in time by the ultraviolet disinfection device, so that the subsequent passengers are prevented from contacting the air possibly carrying the influenza virus, and the risk of influenza transmission is reduced.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This invention provides an H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method, relating to the field of vaccine preparation technology. The H3N2 influenza mRNA vaccine is obtained by linking the conserved amino acid sequences of HA and NA of H3N2 with GGGSGGGSGGGSGGGS, and the amino acid sequence of the H3N2 influenza mRNA vaccine is shown in SEQ ID NO.1, and the nucleic acid sequence is shown in SEQ ID NO.2. This invention overcomes the shortcomings of existing technologies, improves the protective effect of the vaccine against H3N2 influenza, and enables it to better cope with immune evasion from the latest emerging H3N2 variants.

Provided herein are group 2 influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and / or treatment of influenza virus infections.

The invention discloses an influenza reporter virus carrying a fluorescent RNA aptamer and a construction method and application thereof, and the influenza reporter virus carrying the fluorescent RNA aptamer is obtained by introducing a termination codon TAA into the 328th nucleotide of an ORF region of an NS1 gene on the basis of a genome of an influenza A virus and terminating in advance, then introducing a terminating codon TAA into the 328th nucleotide of the ORF region of the NS1 gene of the influenza A virus; original nucleotides at the 328-480 sites are replaced by forward or reverse RNA aptamers, and the RNA aptamer is obtained. The influenza reporter virus carrying the fluorescent RNA aptamer constructed by the invention also has the characteristics of good virus replication ability, high RNA imaging sensitivity and good specificity on the basis of stable inheritance, can be used for real-time visual observation of virus RNA, and is used for research on virus replication cycle and molecular mechanism related to the virus RNA. Besides, the construction method of the influenza reporter virus carrying the fluorescent RNA aptamer can also be applied to construction of RNA fluorescent reporter viruses of other subtype influenza viruses such as H3N2 and H5N1, and an important tool is provided for real-time tracing of corresponding virus RNA.

The invention belongs to the field of new application of medicines, and particularly relates to application of 4-hydroxyderrisin in preparation of anti-influenza virus medicines. It is found for the first time that 4-hydroxyderrisin can significantly inhibit replication and internalization of influenza A virus H1N1 and has significant anti-influenza virus activity, the median inhibitory concentrations of 4-hydroxyderrisin in MDCK cells and A549 cells are 0.60 M and 0.23 M respectively, and the 4-hydroxyderrisin is low in cytotoxicity and high in safety. Experiments show that 4-hydroxyderrisin plays a role in the early stage of a virus life replication cycle, and plays an antiviral role by inhibiting virus internalization without affecting virus adsorption and neuraminidase activity. The medicine can be prepared into a solid or solution dosage form, is used for preventing and treating influenza, and has a good application prospect.

This document describes multivalent nanoparticle vaccine compositions suitable for use in influenza vaccines. The nanoparticles contain effective amounts of influenza glycoproteins that provide a greater immune response compared to a commercially available influenza vaccine composition. This description also provides vaccine formulation strategies that are cost-effective and convenient for clinical use. Methods for administering the nanoparticle vaccine compositions to a subject are also described.

This invention discloses a method, system, and device for branching the gene sequence of influenza A virus, relating to the field of bioinformatics. The method includes the following steps: reading a user-input phylogenetic tree structure file and a Fasta file; dividing the phylogenetic tree into multiple branches based on a set first custom parameter and the gene sequence data of each cotyledon node; verifying the relationship between branches based on a set second custom parameter, and merging branches whose genetic distance is within a set threshold; verifying the merged branches; and if there are unassigned cotyledon nodes, assigning them to the branch with the closest genetic distance that satisfies the custom parameter, thereby obtaining the final branching result of the influenza A virus gene sequence. The method employed in this invention enables targeted phylogenetic branching based on the characteristics of influenza A virus, improving the accuracy of the branching results.

The application belongs to the field of vaccines and genetic engineering technology, and relates to an H3N2 canine influenza recombinant virus strain and application thereof. Specifically, the application relates to a recombinant canine influenza vaccine strain which is obtained by recombination of the following genes: an HA gene, an NA gene, a PB1 gene, a PB2 gene, a PA gene, an NP gene, an M gene and an NS gene; wherein the sequence of the HA gene is shown as SEQ ID NO:1; and / or the sequence of the NA gene is shown as SEQ ID NO:2. The application also relates to an H3N2 canine influenza recombinant vaccine and a method for preparing the H3N2 canine influenza recombinant vaccine.

The present invention relates to the use of mesenchymal stem cells (MSCs) for enhancing the immune response of elderly or animal subjects to vaccination. According to the application, the defects of spleen stromal cell networks and lymphocyte structures of old subjects can be repaired by applying the MSC in advance, and the immune level of organisms is improved; and the vaccine is injected after a period of time, so that the specific antibody level after vaccine immunization can be improved. The effect can also significantly prevent the elderly subjects from being infected by influenza. Therefore, the MSC has a good application prospect in solving related immune decline of old people.

Described herein are isolated T cell receptors that specifically bind to HPV16, MART1, CMV, EBV, or influenza peptides displayed by HLA, and therapeutic and diagnostic methods of using these isolated TCRs.

The application provides an influenza risk forecast method, device and equipment based on high-impact weather classification, and relates to the technical field of influenza risk forecast. The method comprises the following steps: acquiring weather forecast data of a future period, and determining future high-impact weather process information based on the weather forecast data of the future period; acquiring current high-impact weather process information and previous high-impact weather process information; determining a high-impact weather complexity intensity index according to the previous high-impact weather process information, the current high-impact weather process information and the future high-impact weather process information; and determining an influenza risk forecast level according to the high-impact weather complexity intensity index and a process type of the future high-impact weather process. The application constructs a forecast model based on the evolution law of the high-impact weather process, breaks through the limitation of meteorological element data, accurately associates the internal relationship between the weather change trend and the occurrence and spread of influenza, and forecasts more accurately.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The present invention relates to an aryl sulfonamide compound and its anti-influenza use, belonging to the technical field of biomedicine. The present invention provides a series of aryl sulfonamide compounds represented by the general formula I. Experimental verification shows that the aryl sulfonamide compounds have excellent antiviral activity. The toxicity of the compounds is evaluated by cytopathic effect assay. The compounds provided by the present invention have ideal safety and good development prospects.

The application discloses a kind of polyene compounds and preparation method and application thereof, and belongs to the technical field of marine fungi active ingredient analysis.The application utilizes the polarity difference of polyene compound to extract, separate a series of polyene compounds with novel structure from marine fungi Aspergillus flavipes A series of polyene compounds with novel structure are extracted and separated from the fermentation culture of GE2-6, and through in-vitro anti-influenza and anti-HIV virus tests, it is shown that the polyene compounds provided by the application have good in-vitro anti-influenza or anti-HIV virus activity and low cytotoxicity, and have development prospect in the preparation of anti-influenza and anti-HIV virus drugs.

The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza virus neuraminidase (NA) and can neutralize an influenza virus infection. Also provided are polynucleotides that encode an antibody, vectors that comprise such polynucleotides, host cells that can express the antibodies, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an influenza infection.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.

The invention relates to a high-titer influenza virus seed as well as a preparation method and application thereof, and the preparation method comprises the following steps: S1, obtaining a virus, inoculating the virus into a cell factory, and culturing to obtain a cell supernatant; and S2, carrying out microfiltration on the cell supernatant to remove cell debris in the cell supernatant, carrying out ultrafiltration concentration, and carrying out degerming filtration to obtain the high-titer influenza virus seed. According to the technical scheme, the cell factory is adopted for culturing the virus, the virus is inoculated to the ten-layer cell factory, after culturing, the cell supernatant in the cell factory is harvested, microfiltration is carried out, and the cell debris is removed, so that compared with a conventional method for removing the cell debris through centrifugation, microfiltration needs shorter time, the volume of the supernatant which can be treated at a time is larger, and the cell debris can be removed at a time. The sterile risk is lower; and concentrating the supernate, and sterilizing and filtering after concentration. The virus titer of the virus seed subjected to the preparation process can be increased by 5-10 times, and the impurity content is lower.

Disclosed herein are cap-dependent endonuclease (CEN) inhibitors, compositions comprising them, and methods of their use to treat influenza.